Ethics of access to newly approved expensive medical treatments: multi-stakeholder dialogues in a publicly funded healthcare system

Conclusion: Policies for access to non-reimbursed treatments should address stakeholders’ concerns regarding transparency, equal access and solidarity, and loss of potential health benefits for patients. Multi-stakeholder dialogues are an important tool to help inform policy-making on access to newly approved (too) expensive treatments in countries facing challenges to the sustainability of healthcare systems.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research